Free tool
FAERS Monitor: Defitelio
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 208114 or its brand name (Defitelio, Defibrotide Sodium). Reports on generic versions are filed under their own applications.
Reports
3,584
Serious
3,018
84% of reports
Hospitalization
763
Death reported
1,751
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- off label use1,245
- venoocclusive disease565
- death465
- venoocclusive liver disease347
- multiple organ dysfunction syndrome343
- intentional product use issue198
- hypotension160
- haemorrhage157
- acute graft versus host disease140
- gastrointestinal haemorrhage123
- sepsis121
- renal failure104
- septic shock104
- disease progression99
- cystitis haemorrhagic93
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2016 | 68 |
| 2017 | 126 |
| 2018 | 601 |
| 2019 | 505 |
| 2020 | 503 |
| 2021 | 198 |
| 2022 | 474 |
| 2023 | 617 |
| 2024 | 293 |
| 2025 | 120 |
| 2026 | 79 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,050,575 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| venoocclusive diseaseSignal | 565 | 1709.7 | 1566.0 | 746,081 |
| venoocclusive liver diseaseSignal | 347 | 443.5 | 399.6 | 142,053 |
| acute graft versus host diseaseSignal | 140 | 185.1 | 157.0 | 24,681 |
| cystitis haemorrhagicSignal | 93 | 138.6 | 113.1 | 12,277 |
| multiple organ dysfunction syndromeSignal | 343 | 71.9 | 65.0 | 23,659 |
| septic shockSignal | 104 | 14.1 | 11.6 | 1,248 |
| intentional product use issueSignal | 198 | 13.3 | 11.6 | 2,243 |
| haemorrhageSignal | 157 | 8.8 | 7.6 | 1,085 |
| gastrointestinal haemorrhageSignal | 123 | 8.6 | 7.3 | 826 |
| off label useSignal | 1,245 | 8.4 | 8.0 | 8,391 |
| sepsisSignal | 121 | 6.4 | 5.3 | 545 |
| disease progressionSignal | 99 | 4.9 | 4.0 | 306 |
| hypotensionSignal | 160 | 4.7 | 4.0 | 464 |
| renal failureSignal | 104 | 4.6 | 3.8 | 291 |
| deathSignal | 465 | 3.2 | 2.9 | 717 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.